<DOC>
	<DOC>NCT01363986</DOC>
	<brief_summary>This single-arm, multicenter, open-label study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with whole brain radiotherapy on brain metastases in patients with HER-2 positive breast cancer. The patients will receive Herceptin 4 mg/kg (loading dose) followed by 2 mg/kg for a maximum of 18 weekly cycles. The anticipated time on study treatment is 18 weeks.</brief_summary>
	<brief_title>A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patients, &gt;/=18 years of age Diagnosis of breast carcinoma with HER2 overexpression At least one measurable brain metastasis Patients for whom, according to investigator assessment, whole brain radiotherapy is the best therapeutic option Performance status (WHO) &lt;/=2 Life expectancy &gt;/=3 months Presence of neoplastic meningitis Any prior radiotherapy to the brain Patients for whom, according to investigator assessment, stereotactic radiotherapy is the best therapeutic option Previous neoplasms, other than breast carcinoma, within 5 years since enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>